New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a researc ...

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European Congress on Obesity. Researchers conducted a prospective single-center cohort ...

Hims & Hers offers rare high growth at value pricing, with DCF models pointing to major upside despite volatility and short ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

About 11 million workers who have chronic kidney disease now account for $105 billion in annual employer plan spending.

Key Points The stock market has endless opportunities, but most of them lie beyond the headlines. If you want solid gains, it ...

In an erratic soliloquy before he signed an executive order to bring down the price of prescription drugs, President Donald Trump took aim at the "fat shot drug" he said was an example of how Big ...